BioCentury
ARTICLE | Company News

Mersana, Merck Serono in ADC deal

June 25, 2014 12:24 AM UTC

Mersana Therapeutics Inc. (Cambridge, Mass.) partnered with EMD Serono, the biopharmaceutical division of Merck KGaA (Xetra:MRK), to discover and co-develop next-generation antibody-drug conjugates (ADCs). Merck will provide undisclosed mAbs to Mersana, which will use its Fleximer polymer technology to generate ADCs for multiple undisclosed targets selected by Merck. Mersana will conduct discovery and preclinical development, and Merck will have exclusive, worldwide rights to develop and commercialize the ADCs. ...